Drugs & TargetsFree Oncoceutics expands DRD2 research collaborations with NIH March 17, 2017Vol.43 No.11
Drugs & Targets NICE recommends Vectibix for previously untreated metastatic colorectal cancer March 10, 2017Vol.43 No.10
Drugs & Targets EnGeneIC receives Orphan designation for its technology in glioblastoma multiforme March 10, 2017Vol.43 No.10
Drugs & Targets German Community of Gynecological Oncology acknowledges MammaPrint as having Level 1A clinical evidence March 10, 2017Vol.43 No.10
Drugs & TargetsFree FDA approves Xermelo as first and only treatment for carcinoid syndrome diarrhea March 03, 2017Vol.43 No.09
Drugs & TargetsFree FDA Accepts avelumab BLA for Priority Review for urothelial carcinoma March 03, 2017Vol.43 No.09
Drugs & TargetsFree BMS expands International Immuno-Oncology Network with addition of Columbia and MacCallum Cancer Centre March 03, 2017Vol.43 No.09
Drugs & TargetsFree Exelixis, BMS collaborate on late-stage combination trial in first-line RCC March 03, 2017Vol.43 No.09
Drugs & TargetsFree Exelixis, Roche to evaluate cabozantinib and atezolizumab in solid tumors March 03, 2017Vol.43 No.09
Drugs & TargetsFree Advaxis, SELLAS announce licensing agreement to develop antigen-targeting immunotherapy March 03, 2017Vol.43 No.09
